QGEN vs. RGEN, TECH, PCVX, EXEL, CRSP, NBIX, HALO, RVMD, KRYS, and IMVT
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Repligen (RGEN), Bio-Techne (TECH), Vaxcyte (PCVX), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), Krystal Biotech (KRYS), and Immunovant (IMVT). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
97.6% of Repligen shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 1.1% of Repligen shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Repligen has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Qiagen had 1 more articles in the media than Repligen. MarketBeat recorded 4 mentions for Qiagen and 3 mentions for Repligen. Qiagen's average media sentiment score of 0.77 beat Repligen's score of 0.29 indicating that Repligen is being referred to more favorably in the media.
Repligen received 155 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.03% of users gave Repligen an outperform vote while only 60.95% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 17.37% compared to Qiagen's net margin of 6.51%. Repligen's return on equity of 12.99% beat Qiagen's return on equity.
Repligen presently has a consensus target price of $196.70, indicating a potential upside of 5.66%. Qiagen has a consensus target price of $51.69, indicating a potential upside of 20.97%. Given Repligen's higher possible upside, analysts clearly believe Qiagen is more favorable than Repligen.
Summary
Repligen and Qiagen tied by winning 9 of the 18 factors compared between the two stocks.
Get Qiagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools